FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of August 2005
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
Notice of Results
Holding(s) in Company
Statement re MVA
Acambis to announce second quarter results on 6 September 2005
Cambridge, UK and Cambridge, Massachusetts - 4 August 2005 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) will announce its results for the second
quarter ended 30 June 2005 on Tuesday, 6 September 2005.
A meeting and conference call for analysts will be held at 9.30 am BST. The
analyst meeting will be held at The Brewery, Chiswell Street, London, EC1Y 4SD.
For details, contact Mo Noonan at Financial Dynamics on +44 (0) 20 7269 7116. An
instant replay of the call will be available until 13 September 2005 on
telephone number UK: +44 (0) 20 7365 8427 and US: + 001 (617) 801 6888. The pin
code is 40765575.
An audio webcast of the call will also be available via Acambis' website at
www.acambis.com. The webcast replay will be available until Wednesday, 6
September 2006.
-ends-
Enquiries:
Acambis plc
Lyndsay Wright, VP Communications and Investor Relations:
Tel +44 (0) 1223 275 300
Financial Dynamics
Mo Noonan: Tel +44 (0) 20 7269 7116
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis is establishing a travel vaccines
franchise through its US-based subsidiary Berna Products Corporation, which
markets Vivotif(R), the world's only licensed oral typhoid vaccine, in North
America. Acambis has other potential travel vaccines in development and is also
developing an investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and 2004 Form 20-F, in addition to those
detailed on the Company's website and in the Company's filings made with the
Securities and Exchange Commission from time to time. These forward-looking
statements are based on estimates and assumptions made by the management of
Acambis and are believed to be reasonable, though are inherently uncertain and
difficult to predict. Actual results or experience could differ materially from
the forward-looking statements.
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 8 August 2005 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 5 August 2005, Acambis received notification that, as of the close of
business on 3 August 2005, following a sale of shares, The Goldman Sachs Group,
Inc., ("GS Inc") of 85 Broad Street, New York, NY 10004, USA, was interested in
a total of 4,283,591 ordinary shares of 10p each, representing a 3.99% holding
of Acambis' issued share capital.
Of these 4,283,591 shares:
a) the interest in 261,165 shares arose from an interest held by Goldman,
Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc, acting as custodian;
these shares are, or will be, registered in the name of Goldman Sachs
Securities (Nominees), Limited ("GSSN");
b) the interest in 1,156,200 shares arose from an interest held by a direct
subsidiary of GS&Co, acting as custodian of 578,100 American Depositary
Receipts ("ADRs"); these ADRs are, or will be, held at The Depositary
Trust Company, New York;
c) the interest in 47,630 shares arose from the interest held by GS&Co. a
direct subsidiary of GS Inc, acting as discretionary manager. These shares
are, or will be, registered in the name of GSSN; and
d) the interest in 2,818,596 shares arose from a beneficial interest held by
Goldman Sachs International, a direct subsidiary of GS Inc; these shares
are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275
300
Notes to editors:
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine and
manufacturing emergency-use stockpiles of this investigational vaccine for the
US Government and other governments around the world. Acambis is establishing a
travel vaccines franchise through its US-based subsidiary Berna Products
Corporation, which markets Vivotif(R), the world's only licensed oral typhoid
vaccine, in North America. Acambis has a number of other potential travel
vaccines in development and is also developing an investigational vaccine
against the West Nile virus, which has spread to 47 US States since 1999.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk Factors" in the Company's 2004 Form
20-F, in addition to those detailed on the Company's website and in the
Company's filings made with the Securities and Exchange Commission from time to
time. These forward-looking statements are based on estimates and assumptions
made by the management of Acambis and are believed to be reasonable, though are
inherently uncertain and difficult to predict. Actual results or experience
could differ materially from the forward-looking statements.
Statement re MVA
Cambridge, UK and Cambridge, Massachusetts - 22 August 2005 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) Acambis notes the press release issued by
Bavarian Nordic A/S ("BN") after the market close on Friday, 19 August. In that,
BN said that it had filed two legal actions against Acambis in the US, in
relation to the intellectual property on its MVA smallpox vaccine.
Acambis has not yet received a copy of the legal claims, so is unable to comment
on any of the specifics. However, based on the information in BN's press
release, Acambis believes the claims are without foundation. To the extent that
it is required to do so, Acambis will be vigorously defending its legal
position.
Gordon Cameron, Acambis' Chief Executive Officer, commented:
"We have always maintained, having consulted throughout with external patent
counsel, that we have freedom to research, develop, manufacture and sell our MVA
vaccine candidate. That position still stands and we do not expect either of
the BN legal actions to affect that position, in particular for the current US
Government tender process, for which a Request for Proposals was issued last
week. We continue to believe that we are very well positioned to win an award
under that process."
-ends-
Enquiries:
Acambis:
Gordon Cameron, Chief Executive Officer: Tel +1 (617) 761 4200
David Lawrence, Chief Financial Officer: Tel +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel +44 (0) 1223 275
300
Financial Dynamics:
David Yates/Lucy Briggs: Tel +44 (0) 20 7831 3113
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis is establishing a travel vaccines
franchise through its US-based subsidiary Berna Products Corporation, which
markets Vivotif(R), the world's only licensed oral typhoid vaccine, in North
America. Acambis has other potential travel vaccines in development and is also
developing an investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
About Acambis' NIAID contracts
Acambis has been awarded two contracts by the NIAID for the manufacture and
development of its MVA smallpox vaccine, MVA3000. The first contract, awarded in
February 2003, was for $9.2m. The second, awarded in September 2004, has a $76m
core component requiring clinical testing and manufacture of 500,000 doses of
MVA3000, and an optional element potentially worth $55m for the manufacture of a
further 2.5 million doses of MVA3000. Acambis is co-developing MVA3000 with
Baxter Healthcare SA ("Baxter"), which is providing process development and
manufacturing services.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and 2004 Form 20-F, in addition to those
detailed on the Company's website and in the Company's filings made with the
Securities and Exchange Commission from time to time. These forward-looking
statements are based on estimates and assumptions made by the management of
Acambis and are believed to be reasonable, though are inherently uncertain and
difficult to predict. Actual results or experience could differ materially from
the forward-looking statements.
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
INVESCO Perpetual UK Investment Series Limited ("UK ICVC")
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
Vidacos Nominees Limited
5. Number of shares / amount of stock acquired
346,666 shares
6. Percentage of issued class
0.32%
7. Number of shares / amount of stock disposed
N/a
8. Percentage of issued class
N/a
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
24 August 2005
11. Date company informed
25 August 2005
12. Total holding following this notification
20,410,000 shares
13. Total percentage holding of issued class following this notification
19.02%
14. Any additional information
Notification provided by AMVESCAP as an agent for UK ICVC
Holding for SAR purposes is 29,530,510 shares representing a 27.51% holding
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0) 1223 275 300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown
Date of notification
26 August 2005
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Acambis plc ("the Company")
DISCLOSURE OF INTEREST
The Company received notification on 25 August 2005 that, as of close of
business on 23 August 2005, the Goldman Sachs Group, Inc. no longer held a
disclosable interest in the ordinary shares of 10p each in the Company.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary
Tel: +44 (0) 1223 275 300
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 31 August 2005 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: Director of Communications